The immunogenicity of Shingrix vaccination in HIV infected groups at risk of shingles infection (SAGE)

What is the purpose of this research study?

​

We want to test how well a shingles vaccine works in People living with HIV. Shingles is caused by the chickenpox virus and can cause very painful blistering rash or more severe problems if it occurs elsewhere, such as over the eye. Some people are more likely to get Shingles than others. At the moment, the shingles vaccine is only given to people over 60 who have HIV. We want to see how well the vaccine works in people who 50+ or for young people who have been living with HIV since they were children.

​

The vaccine being tested is called Shingrix. It is routinely used in USA and will now start being used in the UK. Currently in the UK, a different Shingles vaccine is available, this is a “live vaccine” which means it is an altered virus – and so this vaccine cannot be given to people with low CD4 counts and has not been tested in young adults. SHINGRIX is not a live vaccine so can be used safely in everyone.

​

Up to 60 adults in the UK will be enrolled onto the study.​

​

The study is jointly coordinated by Guy's at St Thomas' (Sponsor), Imperial College London, Imperial College Healthcare Trust and The University of Oxford.

The study is funded by GSK.

We expect recruitment to start in Q4 of 2022.